While the Medicare Price Negotiations component of the Inflation Reduction Act (IRA) has garnered a lot of attention, the Part D benefit redesign – and associated shifts in stakeholder liability – is poised to be just as disruptive to standard business practices.

The IRA mandates a series of changes to the Part D program that will shift financial liability from patients to plans and drug manufacturers. Specific highlights include:

  • Implementation of an annual $2000 out-of-pocket (OOP) spending cap for patients
  • Expanded subsidies for low-income enrollees
  • Increased Part D plan liability in the catastrophic phase
  • Limits on annual premium increases

During this webinar, we explored:

  • Anticipated changes to Rx demand due to increased affordability
  • Potential payer responses to risk of greater utilization and increasing liability
  • Strategies and considerations to re-think Part D contracting in this new post-IRA world
  • Considerations around geographic targeting based on affordability dynamics
  • Implications to payer, HCP, and patient engagement

Hear Amber Gilbert, Tanya Swift, and Lisa Cashman discuss the importance of understanding the implication.